1. Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19
- Author
-
Thi Nhu Mai Tran, Bruce Pearson May, Trong Thuan Ung, Mai Khoi Nguyen, Thi Thuy Trang Nguyen, Van Long Dinh, Chinh Chung Doan, The Vinh Tran, Hiep Khong, Thi Thanh Truc Nguyen, Hoang Quoc Huy Hua, Viet Anh Nguyen, Tan Phat Ha, Dang Luu Phan, Truong An Nguyen, Thi Ngoc Bui, Tieu My Tu, Thi Theo Nguyen, Thi Thuy Hang Le, Thi Lan Dong, Trong Hieu Huynh, Phien Huong Ho, Nguyen Thanh Thao Le, Cong Thao Truong, Hoang Phi Pham, Cong Y. Luong, Nie Lim Y, Minh Ngoc Cao, Duy Khanh Nguyen, Thi Thanh Le, Duc Cuong Vuong, Le Khanh Hang Nguyen, and Minh Si Do
- Subjects
COVID-19 ,SARS-CoV-2 ,RBD ,ACE2 ,CHO ,Immunologic diseases. Allergy ,RC581-607 - Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global health concern. The development of vaccines with high immunogenicity and safety is crucial for controlling the global COVID-19 pandemic and preventing further illness and fatalities. Here, we report the development of a SARS-CoV-2 vaccine candidate, Nanocovax, based on recombinant protein production of the extracellular (soluble) portion of the spike (S) protein of SARS-CoV-2. The results showed that Nanocovax induced high levels of S protein-specific IgG and neutralizing antibodies in three animal models: BALB/c mouse, Syrian hamster, and a non-human primate (Macaca leonina). In addition, a viral challenge study using the hamster model showed that Nanocovax protected the upper respiratory tract from SARS-CoV-2 infection. Nanocovax did not induce any adverse effects in mice (Mus musculus var. albino) and rats (Rattus norvegicus). These preclinical results indicate that Nanocovax is safe and effective.
- Published
- 2021
- Full Text
- View/download PDF